Mid-term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry.
Female
Humans
Aged
Aged, 80 and over
Male
Transcatheter Aortic Valve Replacement
/ adverse effects
Bicuspid Aortic Valve Disease
Aortic Valve
/ diagnostic imaging
Constriction, Pathologic
Treatment Outcome
Heart Valve Diseases
/ surgery
Aortic Valve Stenosis
/ diagnostic imaging
Mitral Valve Stenosis
Registries
Heart Valve Prosthesis
Transcatheter aortic valve implantation (TAVI)
biscuspid aortic valve stenosis (BAV)
follow-up
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
11
07
2023
received:
15
03
2023
accepted:
16
08
2023
medline:
17
11
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Limited data are available on transcatheter heart valves (THVs) durability in bicuspid aortic valve (BAV) stenosis. To evaluate evaluating 4-year clinical and echocardiographic outcomes of patients with BAV undergoing transcatheter aortic valve implantation (TAVI). The bicuSpid TAvi duraBILITY (STABILITY) registry is an Italian multicentre registry including all consecutive patients with BAV and severe aortic stenosis (AS), treated by means of TAVI between January 2011 and December 2017. Outcomes of interest were all-cause death at 4-year, over time changes in echocardiographic measurements, and THV durability according to the valve aortic research consortium (VARC)-3 update definitions. Study population included 109 patients (50% females; mean age 78 ± 7.5 years) with a mean Society of Thoracic Surgeons Predicted Risk of Mortality score of 5.1 ± 4.3%. Median follow-up (FU) duration was 4.1 years [interquartile range: 2.8-5.1]. The overall cumulative incidence of all-cause death by Kaplan-Meier estimates at 4 years was 32%. Compared to baseline, a significant decrease in transprosthetic mean gradient was obtained after TAVI (54 ± 16 vs. 10 ± 5 mmHg; p < 0.001), whereas a significant increase was observed at 4-year (13 ± 6.4 mmHg, p = 0.03). Cumulative incidence of hemodynamic valve dysfunction (HVD) was 4%. Six patients met HVD criteria: three moderate and three severe HVD. All three cases of severe HVD were clinically relevant (bioprosthetic valve failure [BVF]) with two patients receiving a reintervention (TAVI in TAVI), and one patient experiencing a valve-related death due to endocarditis. The STABILITY registry suggests that in patients with severe AS and BAV undergoing TAVI, postprocedural clinical benefits might last, over time, up to 4-year FU. The low rates of severe HVD and BVF may support the hypothesis of good THV durability also in BAV recipient.
Sections du résumé
BACKGROUND
Limited data are available on transcatheter heart valves (THVs) durability in bicuspid aortic valve (BAV) stenosis.
AIMS
To evaluate evaluating 4-year clinical and echocardiographic outcomes of patients with BAV undergoing transcatheter aortic valve implantation (TAVI).
METHODS
The bicuSpid TAvi duraBILITY (STABILITY) registry is an Italian multicentre registry including all consecutive patients with BAV and severe aortic stenosis (AS), treated by means of TAVI between January 2011 and December 2017. Outcomes of interest were all-cause death at 4-year, over time changes in echocardiographic measurements, and THV durability according to the valve aortic research consortium (VARC)-3 update definitions.
RESULTS
Study population included 109 patients (50% females; mean age 78 ± 7.5 years) with a mean Society of Thoracic Surgeons Predicted Risk of Mortality score of 5.1 ± 4.3%. Median follow-up (FU) duration was 4.1 years [interquartile range: 2.8-5.1]. The overall cumulative incidence of all-cause death by Kaplan-Meier estimates at 4 years was 32%. Compared to baseline, a significant decrease in transprosthetic mean gradient was obtained after TAVI (54 ± 16 vs. 10 ± 5 mmHg; p < 0.001), whereas a significant increase was observed at 4-year (13 ± 6.4 mmHg, p = 0.03). Cumulative incidence of hemodynamic valve dysfunction (HVD) was 4%. Six patients met HVD criteria: three moderate and three severe HVD. All three cases of severe HVD were clinically relevant (bioprosthetic valve failure [BVF]) with two patients receiving a reintervention (TAVI in TAVI), and one patient experiencing a valve-related death due to endocarditis.
CONCLUSIONS
The STABILITY registry suggests that in patients with severe AS and BAV undergoing TAVI, postprocedural clinical benefits might last, over time, up to 4-year FU. The low rates of severe HVD and BVF may support the hypothesis of good THV durability also in BAV recipient.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1132-1139Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Tchetche D, de Biase C, van Gils L, et al. Bicuspid aortic valve anatomy and relationship with devices: the BAVARD multicenter registry. Circ Cardiovasc Interv. 2019;12:e007107.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35-e71.
Montalto C, Sticchi A, Crimi G, et al. Outcomes after transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy. JACC Cardiovasc Interv. 2021;14:2144-2155.
Williams MR, Jilaihawi H, Makkar R, et al. The PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in low-surgical-risk patients. JACC Cardiovasc Interv. 2022;15:523-532.
Deeb GM, Reardon MJ, Ramlawi B, et al. Propensity-matched 1-year outcomes following transcatheter aortic valve replacement in low-risk bicuspid and tricuspid patients. JACC Cardiovasc Imaging. 2022;15:511-522.
Jilaihawi H, Chen M, Webb J, et al. A bicuspid aortic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging. 2016;9:1145-1158.
Généreux P, Piazza N, Alu MC, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77:2717-2746.
Moriyama N, Miyashita H, Lehtola H, et al. Device failure in bicuspid aortic stenosis following transcatheter aortic valve implantation. Am J Cardiol. 2022;176:96-104.
Perlman GY, Blanke P, Dvir D, et al. Bicuspid aortic valve stenosis. JACC Cardiovasc Interv. 2016;9:817-824.
Mangieri A, Tchetchè D, Kim W-K, et al. Balloon versus self-expandable valve for the treatment of bicuspid aortic valve stenosis: insights from the BEAT international collaborative registrys. Circ Cardiovasc Interv. 2020;13:e008714.
Chen C-HJ, Jiang H, Martin O, Wilson-Smith AR. Procedural and clinical outcomes of transcatheter aortic valve replacement in bicuspid aortic valve patients: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2022;11:351-362.
Zhou D, Yidilisi A, Fan J, et al. Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis. EuroIntervention. 2022;18:193-202.
Tchetche D, Ziviello F, De Biase C, et al. Transcatheter aortic valve implantation with the Evolut platform for bicuspid aortic valve stenosis: the international, multicentre, prospective BIVOLUTX registry. EuroIntervention. 2023;19:502-511. doi:10.4244/EIJ-D-23-00021
Gasecka A, Walczewski M, Witkowski A, et al. Long-term mortality after TAVI for bicuspid vs. tricuspid aortic stenosis: a propensity-matched multicentre cohort study. Front Cardiovasc Med. 2022;9:894497.
Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients. Circulation. 2018;138:2597-2607.
Ludman PF, Moat N, de Belder MA, et al. Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation. 2015;131:1181-1190.
Testa L, Latib A, Brambilla N, et al. Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. Eur Heart J. 2020;41:1876-1886.
Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol. 2019;73:546-553.